Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Reports Second Quarter 2015 Financial Results
-- IPO Netted $168 Million for Strong Cash Position -- -- Phase 3 Trial Planned for Early 2016 Based on Successful Phase 2 Trial -- BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 31, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for
Toggle Summary Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 11, 2015-- Aimmune Therapeutics, Inc. , today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the
Toggle Summary Aimmune Therapeutics Announces Pricing of Initial Public Offering
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 5, 2015-- Aimmune Therapeutics, Inc. today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions.
Toggle Summary Aimmune Therapeutics Files Registration Statement for Initial Public Offering
BRISBANE, Calif., July 6, 2015 — Aimmune Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price
Toggle Summary Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101
FDA Breakthrough Therapy Designation for AR101 oral immunotherapy of peanut-allergic children and adolescents follows positive Phase 2 study results BRISBANE, Calif., June 18, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for
Toggle Summary Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy
Positive topline results demonstrate AR101 appears to be a well-tolerated and effective treatment option for peanut allergy in a controlled desensitization regimen, as all study completers in active group met the primary desensitization endpoint Data presented in a late-breaking oral abstract
Toggle Summary Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment
Dr. Wesley Burks of the University of North Carolina will present study data BRISBANE, Calif., June 3, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that the topline results from its Phase 2
Toggle Summary Allergen Research Corporation Renamed Aimmune Therapeutics
BRISBANE, Calif., May 27, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced that the company has changed its name from Allergen Research Corporation (ARC) to Aimmune Therapeutics.
Toggle Summary Allergen Research Corporation Names Mark McDade as Chairman and Mark Iwicki as Member of the Board of Directors
BRISBANE, Calif., May 18, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced additions to the company’s Board of Directors: Mark McDade, joining as Chairman; and Mark Iwicki, joining
Toggle Summary Allergen Research Corporation Announces New CFO Warren DeSouza and Board of Directors Audit Committee Chair Kate Falberg
SAN MATEO, Calif., April 21, 2015 — Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced leadership appointments for the company’s key financial functions.